Medtronic received information via literature regarding the outcomes of patients with pre-existing liver disease who underwent surgical aortic valve replacement or transcatheter aortic valve replacement (tavr) through the transapical (ta-tavr) or transfemoral (tf-tavr) routes.All data were retrospectively collected from a single center between january 2004 and august 2016.The overall study population included 85 patients and was predominantly male with a mean age of 73 years.The tf-tavr subgroup comprised 30 patients and 5 of those were implanted with medtronic corevalve transcatheter bioprosthetic valves.No serial numbers were provided.For the overall study population, the most known causes of death were reported to be sepsis, major bleeding, and low cardiac output/ multi-organ failure/acute liver failure.Among all tf-tavr patients, 5 deaths occurred within one-year of the procedure.Multiple manufacturers transcatheter valves were involved in the tf-tavr subgroup, and based on the available information, medtronic product was not directly associated with the deaths.Among all tf-tavr patients, adverse events included: post-procedural permanent pacemaker implantation; reoperation due to severe bleeding; intra-procedural extracorporeal membrane oxygenation support; gastrointestinal complications (bleeding, subileus, or ileus); sepsis; unspecified infection; unspecified neurological events; major adverse cardiac events; post-procedural percutaneous coronary intervention; aneurysma spurium (pseudoaneurysm); severe aortic insufficiency or paravalvular leak; pericardial tamponade; and high aortic valve gradients.Based on the available information, medtronic product may have been associated with the adverse events.No additional adverse patient effects or product performance issues were reported.
|